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Abstract
Cervical cancer is the fourth common cancer in women resulting worldwide in 266,000
deaths per year. Belonging to the carcinomas, new insights into cervical cancer biology may
also have great implications for finding new treatment strategies for other kinds of epithelial
cancers. Although the transcription factor NF-κB is known as a key player in tumor forma-
tion, the relevance of its particular subunits is still underestimated. Here, we applied
CRISPR/Cas9n-mediated genome editing to successfully knockout the NF-κB subunit c-
REL in HeLa Kyoto cells as a model system for cervical cancers. We successfully generated
a homozygous deletion in the c-REL gene, which we validated using sequencing, qPCR,
immunocytochemistry, western blot analysis, EMSA and analysis of off-target effects. On
the functional level, we observed the deletion of c-REL to result in a significantly decreased
cell proliferation in comparison to wildtype (wt) without affecting apoptosis. The impaired
proliferative behavior of c-REL-/- cells was accompanied by a strongly decreased amount of
the H2B protein as well as a significant delay in the prometaphase of mitosis compared to c-
REL+/+ HeLa Kyoto cells. c-REL-/- cells further showed significantly decreased expression
levels of c-REL target genes in comparison to wt. In accordance to our proliferation data, we
observed the c-REL knockout to result in a significantly increased resistance against the
chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. In summary,
our findings emphasize the importance of c-REL signaling in a cellular model of cervical can-
cer with direct clinical implications for the development of new treatment strategies.
Introduction
Cervical cancer is an epithelial cancer, also called carcinoma, and the fourth common cancer
in women worldwide with an estimated 5-year survival rate of 70% following diagnosis [1, 2].
Based on the degenerated cell type in the uterus, cervical cancer can be classified into
PLOS ONE | https://doi.org/10.1371/journal.pone.0182373 August 2, 2017 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Slotta C, Schlu¨ter T, Ruiz-Perera LM,
Kadhim HM, Tertel T, Henkel E, et al. (2017)
CRISPR/Cas9-mediated knockout of c-REL in HeLa
cells results in profound defects of the cell cycle.
PLoS ONE 12(8): e0182373. https://doi.org/
10.1371/journal.pone.0182373
Editor: Maria Fiammetta Romano, Universita degli
Studi di Napoli Federico II, ITALY
Received: March 21, 2017
Accepted: July 17, 2017
Published: August 2, 2017
Copyright: © 2017 Slotta et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
squamous cell cancer and adenocarcinoma [1]. The most common reason for cervical cancer
is an infection by the human papilloma virus (HPV), namely by HPV 16 and HPV 18 causing
malignant transformations or carcinogenesis in 85% of the diagnosed cases [3, 4]. Treatment
strategies of cervical cancer highly depend on the stage of progression and range from radio-
therapy and surgery [5] to chemotherapy with cisplatin or 5-fluorouracil (5-FU) [6, 7].
Discovered in 1986 [8, 9], the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B-cells (NF-κB) has been shown to play a key role in various cellular pro-
cesses as cell growth, differentiation, apoptosis, inflammation, learning and memory as well as
immunity [10, 11]. Given the importance of NF-κB in these processes, deregulation of its sig-
naling is directly associated to the formation of tumors and cancer progression [12–14], partic-
ularly regarding breast cancer [15] and cervical carcinomas [1]. In 2003, Nair and coworkers
showed a constitutive activation of the NF-κB subunit p65 during human cervical cancer pro-
gression. Here, NF-κB p65 was demonstrated to be particularly activated in high-grade squa-
mous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix [16].
Next to NF-κB p65, the subunit c-REL was shown to possess a key role in tumor formation.
Initial studies demonstrated severe B-cell lymphomas in chickens infected with avian reticu-
loendotheliosis comprising V-REL [17]. Expression of wildtype human c-REL in primary
chicken spleen cell cultures was likewise shown to result in malignant transformation events
[18], although respective mutations increasing the oncogenicity of the c-REL protein in the
avian system were not observable in human cancers (reviewed in [19]). However, amplifica-
tion of c-REL was observed in a broad range of human B-cell lymphomas [20, 21]. In terms of
human cervical cancer, Shehata and coworkers demonstrated a 6-fold slowed cell growth in
cultivated cervical cancer cells by expression of the c-REL homolog Xrel3 from Xenopus laevi
[22]. Accordingly, downregulation of c-REL by small interfering RNA was shown to result in
reduced proliferation of human keratinocytes [23], directly correlating c-REL signaling to
impaired cell cycle progression in a non-cancerous environment. Expression of the c-REL
homolog Xrel3 in human cervical cancer cells was further shown to lead to anti- or pro-apo-
ptotic effects during cisplatin-treatment in a concentration-dependent manner. These findings
emphasize the importance of c-REL-signaling in resistance of cervical carcinoma to chemo-
therapeutic agents [24].
The present study further extends these promising findings by showing a profound overex-
pression of c-REL in cancers located in human ovary, cervix and endometrium using database
mining. To investigate the role of c-REL in human cervical cancers in more detail, we applied
CRISPR/Cas9n-mediated genome editing in a multiplex way to delete c-REL in HeLa Kyoto
cells. Initially discovered as a part of adaptive immune system of bacteria and archaea [25], the
clustered regularly interspaced short palindromic repeats (CRISPR) system has been devel-
oped to a state-of-the-art technique for editing the human genome [26, 27]. Applications of
the CRISPR/Cas9-system particularly include cancer modeling [28] or knockout studies using
human cancer cell lines [27, 29]. In the present study, we applied a Cas9 nickase mutant
(Cas9n) inducing single-strand breaks to minimize the possibility of off-target cleavage in turn
increasing the specificity of genome editing [30].
Using the CRISPR/Cas9n approach, we successfully deleted the c-REL gene on chromo-
somes 2 of HeLa Kyoto cells (c-REL-/-). In comparison to wildtype, c-REL-/- HeLa Kyoto cells
showed a significantly decreased proliferation accompanied by strongly reduced amounts of
histone H2B, a delay in the prometaphase of mitosis and decreased expression levels of c-REL
target genes. We further observed a significantly increased resistance against the chemothera-
peutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin in HeLa Kyoto cells with c-
REL deletion compared to wildtype (wt). Our findings emphasize the importance of c-REL
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signaling in a cellular model of cervical cancer with direct clinical implications concerning the
resistance of cervical carcinoma to chemotherapeutic agents.
Materials and methods
Target design and cloning
The design of the sgRNAs was done using the CRISPR/Cas9n Target Online Predictor from
University of Heidelberg (crispr.cos.uni-heidelberg.de). The gene sequence was taken from
Ensembl Genome Browser (ensembl.org). Two nicking pairs were designed resulting in two
double strand breaks creating a deletion. Nicking pairs were chosen according to the criteria
described by Ran and coworkers [30]. All oligos designed were cloned into one vector essen-
tially as described [31].
Cell culture and transfection
HeLa Kyoto cells [32] were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma
Aldrich, Taufkirchen, Germany) containing high glucose (25 mM), and sodium pyruvate (1
mM). This medium was supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS)
(VWR, Darmstadt, Germany), 2 mM L-glutamine (Sigma Aldrich), 100 U/ml Penicillin/Strep-
tomycin (P/S) (Sigma Aldrich), and 0.5 mg/ml geneticin (G418) (Sigma Aldrich). Cells were
cultivated at 37˚C with 5% CO2 at saturated humidity.
Transfection of HeLa Kyoto cells (3 x 105 cells / transfection) was performed by electropo-
ration using Amaxa Cell Line Nucleofector Kit R (Lonza, Basel, Schweiz) according to the
manufacturer’s protocol. 48 hours after transfection knockout generation was checked by
genomic PCR and cells were used for limiting dilution to obtain clonal c-REL knockout cells.
Genomic PCR and Native PAGE
For cell lysis, cells were harvested at 300 g for 5 min and resuspended in cell lysis buffer
(0.1 μg/mL gelatine, 50 mM KCl, 1.5 mM MgCl2, 0.45% NP40, 10 mM TRIS pH 8.3, 0.45%
TWEEN 20). Proteinase K (20 mg/ml, Serva Electrophoresis, Heidelberg, Germany) was
added followed by incubation of the cell lysate for at least 1 h at 55˚C and 5 min at 95˚C. 2 μL
were used for PCR (c-REL primers: Fw 5´-TGCATTTTCATTTTCAGTGAATGGT-3´,Rev
5´-ACCTGTGGAGATGACTGTGAAG-3´). Resulting bands on agarose gels were extracted
using NucleoSpin Gel and PCR Clean up Kit (Macherey Nagel) according to manufacturer’s
guidelines and subsequently analyzed by sequencing.
For Native PAGE, DNA of the PCR product was denaturized and re-annealed (5 min at
95˚C, -2˚C/s from 95˚C to 85˚C and 0.1˚C/s from 85˚C to 25˚C). PCR product was separated
on a 10% native Polyacrylamide-gel for 2 h at 150 V. Gene Ruler DNA Ladder Mix (Thermo
Fisher Scientific, Waltham, MA, USA) served as marker, gel was immersed in 0.05% ethidium
bromide (Carl Roth GmbH, Karlsruhe, Germany) for 5 min prior to visualization.
Quantitative real-time PCR
RNA isolation was done with NucleoSpin1RNA Kit (Macherey-Nagel) according to
manufacturer’s guidelines. 500 ng RNA were used for cDNA synthesis. Quantitative real-
time PCR (qPCR) was performed using SYBR Green Master Mix (Thermo Fisher Scientific).
cDNA was diluted 1:50 and 2 μL/reaction were used as template. Primer sequences were
5´-CTCCTGACTGACTGACTGCG-3´ (Fw c-REL target deletion), 5´-TACGGGTTATACGC
ACCGGA-3´ (Rev c-REL target deletion), 5´-CCTGGAGCAGGCTATCAGTC-3´ (Fw RELA),
5´-CACTGTCACCTGGAAGCAGA-3´ (Rev RELA), 5´-ACATCAAGGAGAACGGCTTCG-3´
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(Fw RELB), 5´-GACACTAGTCGGCCCAGG-3´ (Rev RELB), 5´-GCACCCTGACCTTGCCTA
TT-3´ (Fw NFKB1), 5´-GCTCTTTTTCCCGATCTCCCA-3´ (Rev NFKB1), 5´-CAACCCAG
GTCTGGATGGTA-3´ (Fw NFKB2), 5´-CTGCTTAGGCTGTTCCACGA -3´ (Rev NFKB2),
5´-TGACAGTGAGCCCTGAAAGC-3´ (Fw IKBKE), 5´-CCGGATTTCCCACACTCTGA-3´
(Rev IKBKE), 5´-CGGAGACCCGGCTGGTATAA-3´ (Fw TBK1), 5´-ATCCACTGGACGAAG
GAAGC-3´ (Rev TBK1), 5´-CTGAAAACGAACGGTGACGG-3´ (Fw A20), 5´-TCCAGTTG
CCAGCGGAATTT-3´ (Rev A20), 5´-CAGGATAACGGAGGCTGGGATG-3´ (Fw BCL2), 5´-
TTCACTTGTGGCCCAGATAGG-3´ (Rev BCL2), 5´-GCTTGGATGGCCACTTACCT-3´ (Fw
BCL-XL), 5´-ACAAAAGTATCCCAGCCGCC-3´ (Rev BCL-XL), 5´-GCAAGTGGACATCAA
CGGGT-3´ (Fw TGFB1), 5´- TCCGTGGAGCTGAAGCAATA-3´(Rev TGFB1), 5´-GTAGT
GGAAAACCAGCAGCC-3´ (Fw MYC), 5´-AGAAATACGGCTGCACCGAG-3´ (Rev MYC),
5´-ATGGCAACGACTCCTTCTCG-3´ (Fw ICAM-1), 5´-GCCGGAAAGCTGTAGATGGT-3´
(Rev ICAM-1). Ct values were normalized to reference genes GAPDH (Fw 5´-CATGAGAAG
TATGACAACAGCCT-3´,Rev 5´-AGTCCTTCCACGATACCAAAGT-3´),RPLP0 (Fw 5´-
TGGGCAAGAACACCATGATG-3´ , Rev 5´-AGTTTCTCCAGAGCTGGGTTGT-3´) and eEF2
(Fw 5´-AGGTCGGTTCTACGCCTTTG-3´,5´-TTCCCACAAGGCACATCCTC-3´).
Western blotting
For analysis of RELA and A20, c-REL-/- and c-REL+/+ cells were treated with human recombi-
nant TNFα (10ng/ml, Calbiochem, Merck, Darmstadt, Germany) for 24h prior to protein iso-
lation. Protein extracts were made using cell lysis buffer (0.01 M TRIS, 3 mM EDTA, 1% SDS)
and equal amounts of protein were separated by SDS-PAGE and transferred to a PVDF mem-
brane. Membranes were blocked using PBS containing 0.05% Tween 20 and 5% milk powder
and probed with primary antibodies (rabbit anti-c-REL (#4727), Cell Signaling Technology,
Danvers, MA, USA); rabbit anti-p65 (#8242), Cell Signaling; mouse anti-A20 (sc-166692),
Santa Cruz Biotechnology, Heidelberg, Germany) overnight at 4˚C. Horseradish peroxidase-
conjugated secondary antibodies were applied for 1h at room temperature and blots were sub-
sequently developed using enhanced chemiluminescence.
Electrophoretic mobility shift assay
Electrophoretic Mobility Shift Assay was performed using DIG Gel Shift Kit, 2nd generation
(Deutschland Holding GmbH, Grenzach-Wyhlen, Germany) according to manufacturer’s
guidelines. For c-REL probe sequence (5´-TCGAGGGCTCGGGCTTTCCATCTCTCGA-3´),
c-REL binding site CGGGCTTTCC was assessed using the JASPAR Tool (jaspar.genereg.net).
Protein isolation procedure and unspecific competitor sequence were applied as described by
Tokunaga and coworkers [33]. PAGE was performed as described above.
Immunocytochemistry and fluorescence imaging of H2B-mcherry
For immunostaining and imaging of H2B-mCherry cells were seeded and cultivated on cover-
slips. Fixation was done by adding 4% paraformaldehyde (PFA) for 10 min. After repetitive
washing using phosphate-buffered saline (PBS), cells were either directly mounted with
Mowiol/DABCO or carried over to immunostaining. For immunocytochemistry, cells were
blocked and permeabilized using 0.02% PBST (PBS with Triton X-100) containing 5% goat
serum for 30 min at RT. Primary antibody (rabbit anti-c-REL (#4727), Cell Signaling; mouse
anti-CD54/ICAM MAB1379, Chemicon, Merck) was applied for 1 h at RT. After washing, cells
were incubated with secondary antibody (goat anti-rabbit Alexa Fluor 647, Thermo Fisher Sci-
entific) for 1 h at RT under exclusion of light. Finally, coverslips were mounted with Mowiol/
DABCO. Imaging was done by confocal laser scanning microscopy (LSM 780, Carl Zeiss,
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Oberkochen, Germany) and image processing was done using Fiji) and Adobe Photoshop CS6
(Adobe Systems, San Jose´, USA) or Corel Draw (Corel Corporation, Ottawa, Canada).
Proliferation & survival assay
Proliferation was analyzed with Orangu Cell Proliferation Assay Kit (Cell Guidance Systems,
Cambridge, UK) used following the manufacturer’s protocol. Cells were counted with Cell-
ometer Auto T4 Cell Viability Counter (Nexcelom, Lawrence, USA). For a calibrating curve
1000, 2500, 5000, 7500, 10000 and 15000 wildtype cells were seeded and incubated for 24 h at
37˚C. For correct cell number determination after one day, one well of each condition was
recounted.
For survival assay 5000 cells in 100 μl were seeded one day before treatment. Cells were
incubated with chemotherapeutic agents cisplatin (CDDP) (P4394, Sigma Aldrich) and
5-Fluoro-2´-deoxyuridine (5-FUDR) (Sigma Aldrich) for 21 h and subsequently Orangu Cell
Proliferation Assay Kit was applied.
Flow cytometric analysis of the cell cycle, apoptosis and histone H2B-
mCherry
DNA content measurement for analyzing cell cycle parameters was performed according to
Kaltschmidt and colleagues [34] by harvesting 1 x 106 cells at 300 g for 5 min followed by fixa-
tion with 70% (v/v) ethanol. After centrifugation at 300 x g for 10 minutes, staining solution
(PBS containing 1 mg/ml glucose (Carl Roth GmbH), 4´,6-diamidino-2-phenylindole (DAPI;
0.5 mg/ml; Sigma-Aldrich), and 100 Kunitz units RNaseA (Thermo Fisher Scientific) was
applied for 60 min under exclusion of light.
For apoptosis measurement, 1 x 106 cells were labeled with Annexin V-PE (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s instructions. For analysis of
H2B-mCherry, 1 x 106 c-REL+/+ and c-REL-/- cells were harvested and directly applied for flow
cytometric analysis without additional staining procedures.
DAPI or Annexin V-PE-labeled cells as well as unstained cells (H2B-mCherry) were ana-
lyzed using a Gallios™ 10/3 flow cytometer (Beckman Coulter, Brea, CA, USA). Data analysis
was performed using FlowJo Software (TreeStar, Olten, Switzerland), doublet discrimination
for cell cycle analysis was assured by appropriate gating strategies.
Live cell imaging
We imaged H2B-mCherry alpha-tubulin-eGFP expressing HeLa Kyoto c-REL+/+ and c-REL
-/- cells in growth conditions at 37 degrees for more than 20 hours with a DeltaVision Elite
imaging system (GE Healthcare). At 20x magnification (Olympus UPlanSApo 20x 0.75), we
recorded on a CoolSNAP HQ2 (Photometrics, USA) CCD camera 15 different lateral positions
with 3 axial position with 1μm spacing for each c-REL+/+ and c-REL-/- cells respectively every
10 minutes for each fluorescent emission channels (LED excitation source 461-489nm, 553-
597nm and emission filtered at 501-549nm, 603-647nm respectively). A DIC image was
recorded for reference at each timepoint. The fluorescent images were deconvolved with the
appropriate OTF in SoftWoRx (version 6.1.3, GE Healthcare), analysed with Fiji and figures
were prepared with Omero.
Promoter analysis
Sequence of promoter regions (1500 bp downstream and 100 bp upstream to respective ATG,
5000 bp downstream for c-Myc promoter) of interest were taken from Eukaryotic Promoter
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Database (epd.vital-ti.ch) for Homo sapiens. Binding sites for gene of interest in chosen pro-
moter sequence were looked up using JASPAR Tool (jaspar.genereg.net). A relative score
threshold of 85% was used. RELA and c-REL binding sites were compared in promoter regions
of selected target genes.
Statistics
All statistical tests were performed with PrismGraph Pad 5 (GraphPad Software, La Jolla,
USA). Statistical significance of qPCR results and fluorescence intensity quantification was
analyzed using unpaired t-test. Welch correction was performed, if variances were significantly
different. Data of proliferation and survival assays were shown to be not normally distributed
(Shapiro-Wilk test) and analyzed using Kruskal-Wallis test with Dunn post-hoc test.
Results
c-REL is overexpressed in human cervical cancers
To assess the clinical implications of a c-REL knockout, we assessed levels of c-REL overexpres-
sion in human cancers by database mining using COSMIC [35]. We found c-REL to be pro-
foundly overexpressed in human cancers, particularly within those located in human ovary,
cervix and endometrium in comparison to oesophagus (Fig 1A, cancer.sanger.ac.uk; 02-14-
2017 16:00; 02-21-2017 15:10). Due to their human cervix origin, we decided to apply HeLa
Kyoto cells for the CRISPR/Cas9n-mediated c-REL knockout.
Successful knockout of c-REL in HeLa Kyoto cells using CRISPR/Cas9n
To generate a c-REL knockout in HeLa Kyoto cells, we designed a target deletion around 450
bp between intron 1 and exon 2 of chromosome 2 using the CRISPR/Cas9 Target Online Pre-
dictor tool (Fig 1B, [36], crispr.cos.uni-heidelberg.de). All designed oligonucleotides were
cloned into an all-in-one vector according to Golden Gate Assembly method (mCRISPR, [31])
allowing easier generation of knockouts. Genomic PCR depicted a profound deletion of the
Fig 1. Assessment of c-REL overexpression in human cancers and target design of CRISPR/Cas9n-mediated c-REL knockout. A: Database
mining revealed more profound overexpression of c-REL in cancers from human ovary, cervix and endometrium compared to oesophagus ([35], sancer.
sanger.ac.uk; 02-14-2017 16:00; 02-21-2017 15:10). B: Target design showing the proposed c-REL knockout with an expected deletion around 450 bp
targeting the intron 1-exon 2-boundary of the c-REL gene. The design was done with the CRISPR/Cas9n Target Online Predictor from the University of
Heidelberg [36], crispr.cos.uni-heidelberg.de) and the gene sequence was taken from Ensembl Genome Browser (ensembl.org).
https://doi.org/10.1371/journal.pone.0182373.g001
c-REL deletion results in cell cycle defects
PLOS ONE | https://doi.org/10.1371/journal.pone.0182373 August 2, 2017 6 / 19
c-REL gene in clonally grown HeLa Kyoto cells after transfection with the constructed
CRISPR/Cas9 vector in comparison to untransfected HeLa Kyoto wt cells (Fig 2A). Sequenc-
ing analysis confirmed the knockout of around 433 bp in exon 2 of c-REL within the trans-
fected HeLa Kyoto clone.
CRISPR/Cas9n-mediated c-REL knockout can be validated on mRNA
and protein level
After initial analysis of the c-REL knockout on DNA level, we assessed the expression level of
c-REL in the HeLa Kyoto knockout clone by qPCR with primers in the targeted deletion. In
contrast to HeLa Kyoto wt cells showing a robust expression of c-REL on mRNA level, no
expression was detectable in the c-REL knockout clone (Fig 2C). Notably, we analysed the top
three predicted exonic off-targets and detected no significant signs of off-target effects in the c-
REL kockout clone (S1 Fig).
Fig 2. Successful validation of the c-REL knockout in HeLa Kyoto cells on DNA, mRNA and protein level. A: Genomic PCR depicting a profound
deletion of the c-REL gene in the c-REL knockout clone (band at 300 bp) compared to the wt clone (band at 700 bp). B: Sequencing analysis confirmed the
knockout in exon 2 of c-REL. C: qPCR with specific primers in targeted deletion of exon 2 showed no expression of c-REL on mRNA level in the c-REL
knockout clone in comparison to wt. D: Western blot analysis validated the knockout of c-REL on protein level. E: Electrophoretic mobility shift assays
(EMSA) showed DNA-binding of c-REL in HeLa Kyoto wt cells (arrow), which was not observable in the c-REL KO clone. F: Immunocytochemistry
depicted a nearly complete loss of c-REL-protein in c-REL knockout clone compared to HeLa Kyoto wt cells.
https://doi.org/10.1371/journal.pone.0182373.g002
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In contrast to HeLa Kyoto wt cells, no c-REL protein was detectable in knockout cells by
western blot analysis even after TNFα-dependent stimulation, confirming the knockout of c-
REL on protein level (Fig 2D). Assessing a potential loss in functionality of the c-REL protein,
we investigated DNA binding activity of c-REL using electrophoretic mobility shift assay
(EMSA). c-REL-/- cells showed no DNA-binding activity of c-REL (Fig 2E), whereas a clear
shift was observable using HeLa Kyoto wt cells (Fig 2E, arrow). Immunocytochemistry further
validated the c-REL knockout in the transfected HeLa Kyoto clone by showing a nearly com-
plete loss of c-REL protein in comparison to HeLa Kyoto wt cells (Fig 2F).
CRISPR/Cas9n-mediated deletion of c-REL results in a decreased
proliferation of HeLa Kyoto cells without affecting apoptosis
We next analyzed potential effects of the c-REL knockout on proliferation and apoptosis of
HeLa Kyoto cells. Using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems), prolif-
eration of c-REL knockout and wt cells was assessed after 2 days. HeLa Kyoto c-REL-/- cells
showed a strongly increased population doubling time of 26.54 h compared to wt HeLa Kyoto
cells displaying a population doubling time of 15.68 h (Fig 3A). This robustly decreased prolif-
erative behavior of c-REL knockout cells was accompanied by a 0.81 fold decrease in the
amount of mitotic cells compared to wildtype, as shown by cell cycle analysis using flow cyto-
metric DNA content measurements (Fig 3B). However, we observed only slightly increased
levels of Annexin V-positive apoptotic cells in c-REL-/- cells compared to wt cells (Fig 3C),
indicating the effect of the c-REL knockout on proliferation of HeLa Kyoto cells to be apopto-
sis-independent.
c-REL-/- HeLa Kyoto cells reveal strongly reduced levels of histone H2B
accompanied by a significantly delayed prometaphase or complete
arrest of the cell cycle
Assessing the reduced proliferative behavior of c-REL-/- HeLa Kyoto cells in more detail, we
analyzed the protein level of histone H2B, which is fused to mCherry in HeLa Kyoto cells [32].
Flow cytometric analysis of H2B-mCherry showed a strongly decreased amount of the H2B
protein in 41.48% of c-REL-/- HeLa Kyoto cells. On the contrary, we observed a reduced H2B
protein level in only 8.67% of HeLa Kyoto wt cells (Fig 3D). Taking advantage of the H2B-
mCherry and alpha-tubulin-EGFP fusion in HeLa Kyoto cells, we further visualized the differ-
ent stages of mitosis in fixed cell samples and living cells. Fluorescence imaging of fixed cells
revealed a significantly increased amount of c-REL-/- HeLa Kyoto cells within the prometa-
phase compared to wt cells (Fig 4E). We investigated this effect of the c-REL deletion in more
detail by live cell imaging. Here, c-REL-/- cells showed a length of the prometaphase of
39.50 ± 9.96 min, which was significantly delayed in comparison to wt cells revealing a dura-
tion of the prometaphase of 18.42 ± 1.58 min (Fig 4A–4C, S1 Movie). In addition, we observed
only 5.4% of wt cells but 25.7% of c-REL-/- cells (n = 40) to arrest during mitosis without entry
of the G2 phase of the cell cycle (Fig 4D, S2 Fig).
c-REL knockout leads to significantly decreased expression levels of
NF-κB family members and cell cycle-associated c-REL target genes
Analyzing effects of the c-REL knockout in HeLa Kyoto cells on other NF-κB family members,
we assessed respective gene expression levels by qPCR. c-REL knockout cells revealed signifi-
cantly decreased mRNA levels of RELA,NFKB1 (p50),NFKB2 (p52), IκB-Kinase ε (IKBKE)
c-REL deletion results in cell cycle defects
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and TANK-binding kinase 1 (TBK1) compared to wildtype cells (Fig 5A). On the contrary,
expression levels of RELB were not significantly affected in the c-REL knockout clone (Fig 5A).
In accordance to the observed decrease in proliferation and in c-REL knockout cells, we fur-
ther observed significantly decreased mRNA levels in cell cycle-related c-REL target genes. In
particular, expression levels of A20 (TNFAIP3), B-cell lymphoma 2 (BCL2), B-cell lymphoma-
extra large (BCLXL, BCL2L1) and transforming growth factor beta 1 (TGFB1) were found to
be significantly decreased in comparison to HeLa Kyoto wildtype cells (Fig 5B). In addition,
expression levels of the c-REL target genes MYC and Intercellular Adhesion Molecule 1
(ICAM-1) were likewise significantly decreased compared to wildtype HeLa Kyoto cells (Fig
5C).
Promoter analysis was further performed using the JASPAR Tool (jaspar.genereg.net) to
validate the analyzed genes to be direct c-REL target genes. Binding sites for c-REL and RELA
were analyzed in each promoter region and their presence confirmed IKBKE, TBK1,A20,
BCL2, BCL-XL, TGFB1,MYC and ICAM-1 to be direct c-REL target genes (S3 Fig).
Fig 3. CRISPR/Cas9-mediated deletion of c-REL results in a decreased proliferation of HeLa Kyoto cell accompanied by strongly reduced
amounts of histone H2B. A: Cell number assessed by Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) set against cultivation time
showed a strongly increased population doubling time of c-REL knockout cells compared to wt HeLa Kyoto cells. PDT: Population doubling time. B:
Flow cytometric DNA content measurements of DAPI-stained c-REL knockout cells showed a decrease in the amount of mitotic cells in c-REL
knockout cells compared to wildtype. C: Flow cytometric analysis of Annexin V-stained c-REL-/- and wt HeLa Kyoto cells revealed only slightly
increased amounts of apoptotic cells upon c-REL deletion in comparison to wt. D: Flow cytometric analysis of histone H2B-mCherry showed a
strongly decreased amount of the H2B protein in 41.48% of c-REL-/- HeLa Kyoto cells, which was observable in only 8.67% of HeLa Kyoto wt cells.
https://doi.org/10.1371/journal.pone.0182373.g003
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Fig 4. Knockout of c-REL leads to a significantly delayed prometaphase or even complete arrest of the cell cycle. A-B: Live cell imaging of c-
REL-/- and c-REL+/+ cells showed delayed duration of the prometaphase in c-REL-/- (arrows) in comparison to wildtype. Mitosis was visualized by H2B-
mCherry and alpha-tubulin-EGFP. C: Quantification of life cell imaging validated the significant delay of c-REL-/- in length of the prometaphase
(39.50 ± 9.96 min) in comparison to wt (18.42 ± 1.58 min) (n = 20). D: Exemplary images of c-REL-/- cells arresting during mitosis without entry of the G2
phase of the cell cycle. E: Fluorescence imaging of H2B-mCherry in fixed cells displayed a significantly increased amount of c-REL-/- HeLa Kyoto cells
within the prometaphase compared to wt cells. (>1000 cells quantified per genotype, n = 3). Scale bar: 25 μm.
https://doi.org/10.1371/journal.pone.0182373.g004
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To validate the decreased expression levels of c-REL target genes in c-REL-/- HeLa Kyoto
cells on protein level, we performed western blot analysis and immunocytochemistry. Western
blot analysis revealed reduced amounts of RELA and A20 protein in c-REL-/- cells in compari-
son to wt (Fig 5D). We further observed a nearly complete loss of ICAM protein in c-REL-/-
cells by immunocytochemistry, while HeLa Kyoto wt cells showed an unchanged amount of
ICAM protein (Fig 5E).
Fig 5. c-REL knockout leads to significantly decreased expression levels of NF-κB family member and cell
cycle-associated genes. A: qPCR analysis showing significantly decreased mRNA levels of NF-κB family
members RELA, NFKB1 (p50), NFKB2 (p52), IKBKE and TBK1 in c-REL knockout cells compared to wildtype
cells. B-C: Expression levels of cell cycle-related c-REL target genes A20, BCL2, BCL-XL and TGFB1 and c-REL
target genes MYC and ICAM-1 were significantly decreased in c-REL knockout cells in comparison to HeLa Kyoto
wildtype cells. D: Western blot analysis validated the reduced expression levels of RELA and A20 in c-REL-/- cells
in comparison to wt on protein level. WB were performed after TNFα-dependent stimulation of c-REL-/- and c-
REL+/+ cells. E: Immunocytochemistry revealed a strongly decreased protein amount of ICAM in c-REL-/- cells in
comparison to wt.
https://doi.org/10.1371/journal.pone.0182373.g005
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HeLa Kyoto cells with c-REL deletion show a significantly increased
resistance against chemotherapeutic agents
With regards to the assessed overexpression of c-REL in human cancers (Fig 1A), potential
clinical implications of the c-REL knockout were assessed by determining cell survival upon
exposure to the chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin.
Here, treatment with increasing concentration of 0.45–100 μM 5-FUDR for 21 h led to cell
death of both c-REL-/- and wildtype cells (Fig 6A).
However, 5-FUDR-treated c-REL knockout clone showed significantly increased cell num-
bers in comparison to wildtype cells, indicating a profoundly increased resistance against
5-FUDR (Fig 6A). We likewise observed this effect after treatment of HeLa Kyoto wildtype
and knockout cells with cisplatin. While cisplatin-treatment of 0.45–4.5 μM led to cell death of
wildtype cells, assessed cell numbers of the c-REL knockout clone were significantly increased
Fig 6. Significantly increased resistance against chemotherapeutic agents in HeLa Kyoto cells with c-REL deletion. A:
Although both HeLa Kyoto wildtype and c-REL knockout cells showed cell death after treatment with 5-Fluoro-2’-deoxyuridine, the c-
REL knockout clone showed significantly elevated cell numbers in comparison to wildtype cells. Cells were exposed to
chemotherapeutic agents for 21 h, cell numbers were assessed using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) after
2 h of incubation. Cell number of untreated cells were set to 1 and used for comparison. B: Although cisplatin-treatment of 1–4 μM led to
cell death of wildtype cells, survival of the c-REL knockout clone was significantly increased even in comparison to untreated control.
Increasing concentrations of cisplatin (10–100 μM) affected survival of c-REL knockout cells, but cell numbers were still significantly
elevated compared to wildtype. Cells were exposed to chemotherapeutic agents for 21 h, cell numbers were assessed using Orangu
Cell Proliferation Assay Kit (Cell Guidance Systems) after 2 h of incubation. Cell number of untreated cells were set to 1 and used for
comparison (n = 8).
https://doi.org/10.1371/journal.pone.0182373.g006
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even in comparison to untreated control (Fig 6B). Although exposure to increasing concentra-
tions of cisplatin (10–100 μM) also resulted in cell death of c-REL knockout cells, cell number
were still found to be significantly increased compared to wildtype, validating a robust resis-
tance against cisplatin (Fig 6B).
Discussion
The present study shows a successful CRISPR/Cas9n-mediated knockout of the NF-κB subunit
c-REL in HeLa Kyoto cells. HeLa cells are one of the most frequently used model systems for
epithelial and in particular cervical cancers [37–39]. Here, we observed a significantly
decreased proliferation of c-REL-/- cells accompanied by a significant decline in expression lev-
els of NF-κB target genes in comparison to wt cells. HeLa Kyoto cells with c-REL deletion fur-
ther revealed a significantly increased resistance against the chemotherapeutic agents
5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. These are commonly used as the trade-
marked chemotherapeutics Platinol1 and FUDR1 in the clinic.
With NF-κB being involved in many cellular processes [10, 11], a broad range of genes were
described to be direct targets of NF-κB, including cytokines, chemokines, cell adhesion mole-
cules, cell surface receptors, regulators of apoptosis and growth factors [40]. Interestingly, par-
ticular subunits of NF-κB were only rarely directly linked to specific target genes. In the present
study, c-REL-/- HeLa Kyoto cells showed significantly decreased expression levels of NF-κB fam-
ily members RELA,NFKB1,NFKB2 as well as IKBKE and TBK1. We also observed several c-
REL binding sites in the promoter region of the TBK1 and IKBKE gene, suggesting TBK1 and
IKBKE as direct c-REL target genes. In addition to their role in phosphorylating NF-κB p65
[41], TBK1 and IKBKE were in turn described to directly phosphorylate the C-terminal domain
of the c-REL protein resulting in its nuclear accumulation [42]. Extending these promising find-
ings, we suggest a positive feedback loop by c-REL-mediated expression of TBK1 and IKBKE in
turn leading to a pronounced activation of c-REL. Being also closely linked to the pathogenesis
of breast cancer by promoting activation of NF-κB [43], targeting IKBKEmay be an interesting
future perspective for developing new treatment strategies against cervical cancer. Next to
TBK1 and IKBKE, c-REL knockout was observed to be sufficient to downregulate the expression
of MYC in growing HeLa cells by more than 50% with the relative MYC expression being highly
elevated in comparison to other target genes. Accordingly, Grumont and coworkers showed an
impaired expression of MYC in stage III thymocytes with a RELA/c-REL double knockout [44].
We also demonstrated the presence of three c-REL binding sites in the downstream region of
the MYC promoter, further validating MYC as a direct target gene of c-REL.
In comparison to wildtype, c-REL-/- HeLa Kyoto cells further revealed a significantly
decreased expression of BCL-2, BCL-XL and A20, which are commonly known as anti-apopto-
tic genes [45, 46]. In accordance to our promoter analysis depicting c-REL-binding sites,
BCL-XL and BCL2were described to be direct c-REL target genes [47, 48]. Expression of
TGFB1, already known as direct target of c-REL [49] and a common inducer of cell prolifera-
tion [50], was also significantly reduced in c-REL-/- HeLa Kyoto cells. On functional level, we
observed the c-REL knockout to result in a significantly reduced proliferation, which we sug-
gest to be at least in part mediated by the depicted decline in pro-proliferative target gene
expression. In consistence with these findings, knockdown of the c-REL target gene IKBKE in
HeLa cells was also shown to result in a suppression of proliferation [51]. In human keratino-
cytes, small interfering RNA-mediated knockdown of c-REL was reported to directly affect cell
cycle progression by cell cycle delay of the G2/M phase [23]. The present study further
extended these findings by showing the CRISPR-Cas9n-mediated knockout of c-REL to result
in a robustly delayed prometaphase of mitosis accompanied by strongly reduced levels of
c-REL deletion results in cell cycle defects
PLOS ONE | https://doi.org/10.1371/journal.pone.0182373 August 2, 2017 13 / 19
histone H2B protein. In addition, we observed a novel linkage between the decreased amount
of histone H2B protein and the prolonged prometaphase in c-REL-/- cells. In mice, silencing of
c-Rel by siRNA was shown to lead to a reduction of mitosis in a B cell tumor cell line [52]. Gru-
mont and coworkers likewise demonstrated a cell cycle arrest in B-cells of c-Rel-/- mice [53].
Our present findings for the first time transfer these promising data to the human cancerous
systems and provide deeper insights into the biology of cervical cancers in relation to c-REL-
signaling. In this regard, we were also able to observe significantly reduced expression levels of
ICAM1 in c-REL-/- HeLa Kyoto cells. Downregulation of this adhesion molecule was described
to result in a suppression of human breast cancer cell invasion with the level of expression
being directly correlated to their metastatic potential [54]. Accordingly, inhibition of MYC
protein family members have been shown to induce regression of lung cancer in mice [55],
suggesting the downregulation of MYC observed here likewise to be linked to the reduced pro-
liferation of c-REL-/- cells.
The NF-κB subunit c-REL is also directly linked to cancer development and progression. In
1999, Krappmann and colleagues described a constitutive NF-κB-activity with NF-κB-com-
plexes containing RELA and c-REL in malignant cells derived from Hodgkin’s disease [56].
Whereas c-REL was currently discussed as being mutated in hematopoietic and lymphoid
tumors [57], a high throughput database analysis performed in the present study including
3397 hematopoietic and lymphoid tumors detected mutations in only a few samples [35, 58].
In 2004, Futreal and coworkers described a ‘census’ of human cancers indicating mutations in
>1% of genes of the human genome to contribute to cancer, although genes showing solely
altered expression levels were not included in this initial ‘census’ [59]. Here, we applied data-
base mining using the COSMIC database [35] and observed profound overexpression of c-REL
in various human tumors (Table 1), which is in accordance to the observed amplification of c-
REL in human B-cell lymphomas [20, 21]. Likewise in line with previous studies, c-REL can be
Table 1. Overexpression of REL in human cancers.
tissue type % of REL overexpression no. tested
Ovary 7.52 266
Lung 7.26 1019
Urinary tract 7.11 408
Endometrium 6.81 602
Pancreas 6.7 179
Haematopoietic and lymphoid 6.33 221
Soft tissue 6.08 263
Cervix 5.86 307
Upper aerodigestive tract 5.75 522
Kidney 5.5 600
Thyroid 5.46 513
Large intestine 4.92 610
Stomach 4.91 285
Liver 4.83 373
CNS 4.73 697
Prostate 4.62 498
Breast 3.71 1104
Skin 3.59 473
Oesophagus 3.2 125
Adrenal gland 2.53 79
https://doi.org/10.1371/journal.pone.0182373.t001
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considered as one of the most oncogenic members of the NF-κB family, in fowl reticuloen-
dotheliosis virus also contains mutated oncogenic v-Rel [18, 19, 52, 60].
In the present study, knockout of c-REL in a cellular model of cervical carcinoma resulted
in a significantly increased resistance against the chemotherapeutic agents 5-FUDR and cis-
platin. Due to direct interaction of cisplatin and 5-fluorouracil with the DNA, highly prolifer-
ating cells are exposed to DNA damage resulting in cell-cycle arrest and cell death [61, 62].
Thus, we suggest the reduced proliferation of HeLa c-REL-/- cells to account for the observed
increase in resistance against cisplatin and 5-FUDR. Although activation of NF-κB was also
described to lead to a decreased sensitivity of cancer cells against chemotherapeutic treatment
[63, 64], our present findings propose a subunit specificity of NF-κB in terms of chemoresis-
tance. While a knockout of c-REL promoted survival of HeLa cells to chemotherapy, expres-
sion of the c-REL homolog Xenopus Xrel3 in cervical cancer cells treated with 5 μM cisplatin
was shown to result in increased apoptosis [24].
In summary, our findings emphasize the importance of c-REL-signaling in a cellular model
of cervical cancer particularly in terms of proliferation and resistance to chemotherapeutic
agents. Considering the proposed NF-κB-subunit specificity of chemoresistance, we provide
deeper insights into cervical cancer biology with direct clinical implications for the develop-
ment of new treatment strategies.
Supporting information
S1 Fig. PAGE-analysis of top three predicted exonic off-targets revealed no signs of off-tar-
get effects in the c-REL knockout clone.
(TIF)
S2 Fig. Live cell imaging showing c-REL-/- cells, which arrested during mitosis without
entry of the G2 phase of the cell cycle. Scale bar: 25 μm.
(TIF)
S3 Fig. Promoter analysis using the JASPAR Tool (jaspar.genereg.net) validated IKBKE,
TBK1,A20, BCL2, BCL-XL, TGFB1,MYC and ICAM-1 to be direct c-REL target genes. c-
REL binding site is shown in magenta, RELA binding site is depicted in cyan and common
binding sites are shown in purple.
(TIF)
S1 Movie. Live cell imaging of c-REL-/- and c-REL+/+ cells showed delayed duration of the
prometaphase in c-REL-/- in comparison to wildtype. Mitosis was visualized by H2B-
mCherry and alpha-tubulin-EGFP.
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